{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:32:29Z","timestamp":1794576749019,"version":"4.9.1"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1038\/s41581-024-00908-z","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T14:18:51Z","timestamp":1733494731000},"page":"175-188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Endothelin receptor antagonists in chronic kidney disease"],"prefix":"10.1038","volume":"21","author":[{"given":"J. David","family":"Smeijer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald E.","family":"Kohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9128-6603","authenticated-orcid":false,"given":"Neeraj","family":"Dhaun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene L.","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0963-6270","authenticated-orcid":false,"given":"Adrian","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J. L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"908_CR1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","volume":"332","author":"M Yanagisawa","year":"1988","unstructured":"Yanagisawa, M. et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332, 411\u2013415 (1988).","journal-title":"Nature"},{"key":"908_CR2","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/348732a0","volume":"348","author":"T Sakurai","year":"1990","unstructured":"Sakurai, T. et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348, 732\u2013735 (1990).","journal-title":"Nature"},{"key":"908_CR3","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/348730a0","volume":"348","author":"H Arai","year":"1990","unstructured":"Arai, H., Hori, S., Aramori, I., Ohkubo, H. & Nakanishi, S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348, 730\u2013732 (1990).","journal-title":"Nature"},{"key":"908_CR4","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1124\/pr.115.011833","volume":"68","author":"AP Davenport","year":"2016","unstructured":"Davenport, A. P. et al. Endothelin. Pharmacol. Rev. 68, 357\u2013418 (2016).","journal-title":"Pharmacol. Rev."},{"key":"908_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.00060.2009","volume":"91","author":"DE Kohan","year":"2011","unstructured":"Kohan, D. E., Rossi, N. F., Inscho, E. W. & Pollock, D. M. Regulation of blood pressure and salt homeostasis by endothelin. Physiol. Rev. 91, 1\u201377 (2011).","journal-title":"Physiol. Rev."},{"key":"908_CR6","doi-asserted-by":"crossref","first-page":"S268","DOI":"10.1097\/00005344-199526003-00081","volume":"26","author":"F Karet","year":"1995","unstructured":"Karet, F. & Davenport, A. Comparative quantification of endothelin receptor mRNA in human kidney: new tools for direct investigation of human tissue. J. Cardiovasc. Pharmacol. 26, S268\u2013S271 (1995).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"908_CR7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/ki.1993.210","volume":"44","author":"FE Karet","year":"1993","unstructured":"Karet, F. E., Kuc, R. E. & Davenport, A. P. Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney. Kidney Int. 44, 36\u201342 (1993).","journal-title":"Kidney Int."},{"key":"908_CR8","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/ki.2014.143","volume":"86","author":"DE Kohan","year":"2014","unstructured":"Kohan, D. E. & Barton, M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int. 86, 896\u2013904 (2014).","journal-title":"Kidney Int."},{"key":"908_CR9","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1681\/ASN.2013080830","volume":"25","author":"D de Zeeuw","year":"2014","unstructured":"de Zeeuw, D. et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J. Am. Soc. Nephrol. 25, 1083\u20131093 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"908_CR10","doi-asserted-by":"publisher","unstructured":"Heerspink, H. J. L. et al. Atrasentan in patients with IgA nephropathy. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2409415 (2024).","DOI":"10.1056\/NEJMoa2409415"},{"key":"908_CR11","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","volume":"393","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink, H. J. L. et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 393, 1937\u20131947 (2019).","journal-title":"Lancet"},{"key":"908_CR12","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1681\/ASN.2018010091","volume":"29","author":"H Trachtman","year":"2018","unstructured":"Trachtman, H. et al. DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J. Am. Soc. Nephrol. 29, 2745\u20132754 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"908_CR13","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","volume":"401","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink, H. J. L. et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet 401, 1584\u20131594 (2023).","journal-title":"Lancet"},{"key":"908_CR14","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","volume":"402","author":"BH Rovin","year":"2023","unstructured":"Rovin, B. H. et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet 402, 2077\u20132090 (2023).","journal-title":"Lancet"},{"key":"908_CR15","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1146\/annurev.pharmtox.41.1.851","volume":"41","author":"RM Kedzierski","year":"2001","unstructured":"Kedzierski, R. M. & Yanagisawa, M. Endothelin system: the double-edged sword in health and disease. Annu. Rev. Pharmacol. Toxicol. 41, 851\u2013876 (2001).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"908_CR16","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1161\/01.CIR.0000118499.69469.51","volume":"109","author":"J Goddard","year":"2004","unstructured":"Goddard, J. et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure. Circulation 109, 1186\u20131193 (2004).","journal-title":"Circulation"},{"key":"908_CR17","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1097\/01.ASN.0000141313.84470.4B","volume":"15","author":"J Goddard","year":"2004","unstructured":"Goddard, J. et al. Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism. J. Am. Soc. Nephrol. 15, 2601\u20132610 (2004).","journal-title":"J. Am. Soc. Nephrol."},{"key":"908_CR18","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1161\/HYPERTENSIONAHA.110.167486","volume":"57","author":"N Dhaun","year":"2011","unstructured":"Dhaun, N. et al. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 57, 772\u2013779 (2011).","journal-title":"Hypertension"},{"key":"908_CR19","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1172\/JCI71195","volume":"124","author":"I Daehn","year":"2014","unstructured":"Daehn, I. et al. Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis. J. Clin. Invest. 124, 1608\u20131621 (2014).","journal-title":"J. Clin. Invest."},{"key":"908_CR20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrneph.2017.6","volume":"13","author":"TJ Rabelink","year":"2017","unstructured":"Rabelink, T. J. et al. Heparanase: roles in cell survival, extracellular matrix remodelling and the development of kidney disease. Nat. Rev. Nephrol. 13, 201\u2013212 (2017).","journal-title":"Nat. Rev. Nephrol."},{"key":"908_CR21","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.kint.2019.05.007","volume":"96","author":"K Ebefors","year":"2019","unstructured":"Ebefors, K. et al. Endothelin receptor-A mediates degradation of the glomerular endothelial surface layer via pathologic crosstalk between activated podocytes and glomerular endothelial cells. Kidney Int. 96, 957\u2013970 (2019).","journal-title":"Kidney Int."},{"key":"908_CR22","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1681\/ASN.2015091070","volume":"27","author":"M Garsen","year":"2016","unstructured":"Garsen, M. et al. Endothelin-1 induces proteinuria by heparanase-mediated disruption of the glomerular glycocalyx. J. Am. Soc. Nephrol. 27, 3545\u20133551 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"908_CR23","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.semnephrol.2015.02.005","volume":"35","author":"M Barton","year":"2015","unstructured":"Barton, M. & Sorokin, A. Endothelin and the glomerulus in chronic kidney disease. Semin. Nephrol. 35, 156\u2013167 (2015).","journal-title":"Semin. Nephrol."},{"key":"908_CR24","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1152\/ajprenal.00019.2003","volume":"285","author":"A Sorokin","year":"2003","unstructured":"Sorokin, A. & Kohan, D. E. Physiology and pathology of endothelin-1 in renal mesangium. Am. J. Physiol. Renal Physiol. 285, 579\u2013589 (2003).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"908_CR25","doi-asserted-by":"crossref","first-page":"11003","DOI":"10.1074\/jbc.M110.190793","volume":"286","author":"MS Simonson","year":"2011","unstructured":"Simonson, M. S. & Ismail-Beigi, F. Endothelin-1 increases collagen accumulation in renal mesangial cells by stimulating a chemokine and cytokine autocrine signaling loop. J. Biol. Chem. 286, 11003\u201311008 (2011).","journal-title":"J. Biol. Chem."},{"key":"908_CR26","doi-asserted-by":"crossref","first-page":"R877","DOI":"10.1152\/ajpregu.00425.2015","volume":"310","author":"R Komers","year":"2016","unstructured":"Komers, R. & Plotkin, H. Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease. Am. J. Physiol. Regul. Integr. Comp. Physiol. 310, R877\u2013884 (2016).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"908_CR27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/ndt\/15.suppl_6.50","volume":"15","author":"A Benigni","year":"2000","unstructured":"Benigni, A. Tubulointerstitial disease mediators of injury: the role of endothelin. Nephrol. Dial. Transplant. 15, 50\u201352 (2000).","journal-title":"Nephrol. Dial. Transplant."},{"key":"908_CR28","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1681\/ASN.V12112321","volume":"12","author":"I Lehrke","year":"2001","unstructured":"Lehrke, I., Waldherr, R., Ritz, E. & Wagner, J. Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria. J. Am. Soc. Nephrol. 12, 2321\u20132329 (2001).","journal-title":"J. Am. Soc. Nephrol."},{"key":"908_CR29","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000101999","volume":"27","author":"M Gerstung","year":"2007","unstructured":"Gerstung, M., Roth, T., Dienes, H. P., Licht, C. & Fries, J. W. U. Endothelin-1 induces NF-\u03baB via two independent pathways in human renal tubular epithelial cells. Am. J. Nephrol. 27, 294\u2013300 (2007).","journal-title":"Am. J. Nephrol."},{"key":"908_CR30","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/0272-6386(95)90058-6","volume":"26","author":"C Zoja","year":"1995","unstructured":"Zoja, C. et al. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am. J. Kidney Dis. 26, 934\u2013941 (1995).","journal-title":"Am. J. Kidney Dis."},{"key":"908_CR31","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/ki.2013.157","volume":"84","author":"RA Zager","year":"2013","unstructured":"Zager, R. A., Johnson, A. C. M., Andress, D. & Becker, K. Progressive endothelin-1 gene activation initiates chronic\/end-stage renal disease following experimental ischemic\/reperfusion injury. Kidney Int. 84, 703\u2013712 (2013).","journal-title":"Kidney Int."},{"key":"908_CR32","first-page":"1","volume":"2","author":"KN Lai","year":"2016","unstructured":"Lai, K. N. et al. IgA nephropathy. Nat. Rev. Dis. Prim. 2, 1\u201320 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"908_CR33","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1159\/000188912","volume":"72","author":"T Nakamura","year":"1996","unstructured":"Nakamura, T., Ebihara, I., Fukui, M., Tomino, Y. & Koide, H. Effect of a specific endothelin receptor A antagonist on glomerulonephritis of ddY mice with IgA nephropathy. Nephron 72, 454\u2013460 (1996).","journal-title":"Nephron"},{"key":"908_CR34","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1016\/j.ekir.2021.03.388","volume":"6","author":"J Cox","year":"2021","unstructured":"Cox, J. et al. Human renal mesangial cell activation induced by endothelin-1 or IgA nephropathy patient-derived immune complexes is blocked by selective eta antagonist atrasentan. Kidney Int. Rep. 6, S160\u2013S161 (2021).","journal-title":"Kidney Int. Rep."},{"key":"908_CR35","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1016\/j.ekir.2021.03.396","volume":"6","author":"A King","year":"2021","unstructured":"King, A. et al. Selective ETA antagonist atrasentan, rapidly reduces albuminuria and downregulates intra-renal pro-inflammatory and pro-fibrotic transcriptional networks in the gddY mouse model of spontaneous IgA nephropathy. Kidney Int. Rep. 6, S164 (2021).","journal-title":"Kidney Int. Rep."},{"key":"908_CR36","doi-asserted-by":"crossref","first-page":"gfac067.063","DOI":"10.1093\/ndt\/gfac067.063","volume":"37","author":"E Olson","year":"2022","unstructured":"Olson, E. et al. Selective endothelin a receptor antagonist atrasentan attenuates mesangial cell injury, proteinuria and intra-renal proliferative, inflammatory and fibrotic transcriptional networks in a rat model of mesangioproliferative glomerulonephritis. Nephrol. Dial. Transplant. 37, gfac067.063 (2022).","journal-title":"Nephrol. Dial. Transplant."},{"key":"908_CR37","doi-asserted-by":"crossref","unstructured":"Olson, N., McConnell, M. & McCown, P. Single nuclei RNA-Seq reveals cell-type specific responses to disease and enalapril in the gddY mouse model of IgA nephropathy. ASN Kidney Week Abstract: TH-PO419 (2022).","DOI":"10.1681\/ASN.20223311S1163c"},{"key":"908_CR38","doi-asserted-by":"crossref","first-page":"gfac067.060","DOI":"10.1093\/ndt\/gfac067.060","volume":"37","author":"H Nagasawa","year":"2022","unstructured":"Nagasawa, H. et al. Sparsentan, the dual endothelin angiotensin receptor antagonist (DEARA), attenuates albuminuria and protects from the development of renal injury to a greater extent than losartan in the GDDY mouse model of IGA nephropathy: a 16-week study. Nephrol. Dial. Transplant. 37, gfac067.060 (2022).","journal-title":"Nephrol. Dial. Transplant."},{"key":"908_CR39","doi-asserted-by":"crossref","first-page":"F862","DOI":"10.1152\/ajprenal.00253.2023","volume":"326","author":"C Reily","year":"2024","unstructured":"Reily, C. et al. Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgG immune complexes in a mouse model of IgA nephropathy. Am. J. Physiol. Renal Physiol. 326, F862\u2013F875 (2024).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"908_CR40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/jcla.2","volume":"15","author":"H Chen","year":"2001","unstructured":"Chen, H. et al. Plasma and urinary endothelin\u20101 in focal segmental glomerulosclerosis. J. Clin. Lab. Anal. 15, 59\u201363 (2001).","journal-title":"J. Clin. Lab. Anal."},{"key":"908_CR41","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.ekir.2021.04.013","volume":"6","author":"NA van de Lest","year":"2021","unstructured":"van de Lest, N. A. et al. Endothelial endothelin receptor A expression is associated with podocyte injury and oxidative stress in patients with focal segmental glomerulosclerosis. Kidney Int. Rep. 6, 1939\u20131948 (2021).","journal-title":"Kidney Int. Rep."},{"key":"908_CR42","doi-asserted-by":"crossref","unstructured":"Daehn, I., Yu, L. & Yi, Z. Podocyte-derived endothelin-1 and cross-talk with endothelial cells through EdnrA is essential for glomerular injury. ASN Kidney Week Abstract: FR-OR101 (2023).","DOI":"10.1681\/ASN.20233411S157c"},{"key":"908_CR43","doi-asserted-by":"crossref","unstructured":"Gyarmati, G., Deepak, S. & Shroff, U. Sparsentan improves glomerular endothelial and podocyte functions and augments protective tissue repair in a mouse model of focal segmental glomerulosclerosis. ASN Kidney Week Abstract: FR-OR56 (2022).","DOI":"10.1681\/ASN.20223311S133a"},{"key":"908_CR44","doi-asserted-by":"crossref","first-page":"MO255","DOI":"10.1093\/ndt\/gfac067.054","volume":"37","author":"P Bedard","year":"2022","unstructured":"Bedard, P., Jenkinson, C. & Komers, R. Sparsentan protects the glomerular basement membrane and glycocalyx, and attenuates proteinuria in a rat model of focal segmental glomerulosclerosis. Nephrol. Dial. Transplant. 37, MO255 (2022).","journal-title":"Nephrol. Dial. Transplant."},{"key":"908_CR45","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2337\/diabetes.47.3.450","volume":"47","author":"A Benigni","year":"1998","unstructured":"Benigni, A. et al. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes 47, 450\u2013456 (1998).","journal-title":"Diabetes"},{"key":"908_CR46","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000020519","volume":"6","author":"C Zoja","year":"1998","unstructured":"Zoja, C. et al. Angiotensin II blockade limits tubular protein overreabsorption and the consequent upregulation of endothelin 1 gene in experimental membranous nephropathy. Exp. Nephrol. 6, 121\u2013131 (1998).","journal-title":"Exp. Nephrol."},{"key":"908_CR47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099083","volume":"9","author":"D Delimont","year":"2014","unstructured":"Delimont, D. et al. Laminin \u03b12-mediated focal adhesion kinase activation triggers Alport glomerular pathogenesis. PLoS ONE 9, e99083 (2014).","journal-title":"PLoS ONE"},{"key":"908_CR48","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.kint.2016.02.018","volume":"90","author":"B Dufek","year":"2016","unstructured":"Dufek, B. et al. Endothelin A receptor activation on mesangial cells initiates Alport glomerular disease. Kidney Int. 90, 300\u2013310 (2016).","journal-title":"Kidney Int."},{"key":"908_CR49","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/path.6087","volume":"260","author":"D Cosgrove","year":"2023","unstructured":"Cosgrove, D. et al. Dual inhibition of the endothelin and angiotensin receptor ameliorates renal and inner ear pathologies in Alport mice. J. Pathol. 260, 353\u2013364 (2023).","journal-title":"J. Pathol."},{"key":"908_CR50","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0895-7061(02)03060-1","volume":"15","author":"JG Schneider","year":"2002","unstructured":"Schneider, J. G. et al. Elevated plasma endothelin-1 levels in diabetes mellitus. Am. J. Hypertens. 15, 967\u2013972 (2002).","journal-title":"Am. J. Hypertens."},{"key":"908_CR51","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1681\/ASN.2006030208","volume":"18","author":"JM Sasser","year":"2007","unstructured":"Sasser, J. M. et al. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J. Am. Soc. Nephrol. 18, 143\u2013154 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"908_CR52","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000045906","volume":"87","author":"B Hocher","year":"2001","unstructured":"Hocher, B. et al. Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron 87, 161\u2013169 (2001).","journal-title":"Nephron"},{"key":"908_CR53","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1681\/ASN.2013020195","volume":"25","author":"O Lenoir","year":"2014","unstructured":"Lenoir, O. et al. Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis. J. Am. Soc. Nephrol. 25, 1050\u20131062 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"908_CR54","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.2337\/db15-1413","volume":"65","author":"MGS Boels","year":"2016","unstructured":"Boels, M. G. S. et al. Atrasentan reduces albuminuria by restoring the glomerular endothelial glycocalyx barrier in diabetic nephropathy. Diabetes 65, 2429\u20132439 (2016).","journal-title":"Diabetes"},{"key":"908_CR55","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1161\/CIRCULATIONAHA.105.563213","volume":"113","author":"JA Kim","year":"2006","unstructured":"Kim, J. A., Montagnani, M., Kwang, K. K. & Quon, M. J. Reciprocal relationships between insulin resistance and endothelial dysfunction. Circulation 113, 1888\u20131904 (2006).","journal-title":"Circulation"},{"key":"908_CR56","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000045519","volume":"83","author":"MA Khan","year":"1999","unstructured":"Khan, M. A. et al. Upregulation of endothelin A receptor sites in the rabbit diabetic kidney: potential relevance to the early pathogenesis of diabetic nephropathy. Nephron 83, 261\u2013267 (1999).","journal-title":"Nephron"},{"key":"908_CR57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fj.03-0013fje","volume":"17","author":"AG Minchenko","year":"2003","unstructured":"Minchenko, A. G. et al. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J. 17, 1\u201318 (2003).","journal-title":"FASEB J."},{"key":"908_CR58","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/00005344-200312000-00009","volume":"42","author":"A Cosenzi","year":"2003","unstructured":"Cosenzi, A. et al. Nephroprotective effect of bosentan in diabetic rats. J. Cardiovasc. Pharmacol. 42, 752\u2013756 (2003).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"908_CR59","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00005344-200307000-00008","volume":"42","author":"SS Ding","year":"2003","unstructured":"Ding, S. S. et al. Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat. J. Cardiovasc. Pharmacol. 42, 48\u201354 (2003).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"908_CR60","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.lfs.2012.07.034","volume":"91","author":"DE Kohan","year":"2012","unstructured":"Kohan, D. E., Cleland, J. G., Rubin, L. J., Theodorescu, D. & Barton, M. Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci. 91, 528\u2013539 (2012).","journal-title":"Life Sci."},{"key":"908_CR61","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1093\/ndt\/gfad078","volume":"38","author":"V Veenit","year":"2023","unstructured":"Veenit, V. et al. The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan. Nephrol. Dial. Transplant. 38, 2289\u20132297 (2023).","journal-title":"Nephrol. Dial. Transplant."},{"key":"908_CR62","doi-asserted-by":"crossref","first-page":"12823","DOI":"10.3390\/ijms232112823","volume":"23","author":"A Vergara","year":"2022","unstructured":"Vergara, A. et al. Enhanced cardiorenal protective effects of combining SGLT2 inhibition, endothelin receptor antagonism and RAS blockade in type 2 diabetic mice. Int. J. Mol. Sci. 23, 12823 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"908_CR63","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1681\/ASN.2010080869","volume":"22","author":"DE Kohan","year":"2011","unstructured":"Kohan, D. E. et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J. Am. Soc. Nephrol. 22, 763 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"908_CR64","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1681\/ASN.2008050482","volume":"20","author":"RR Wenzel","year":"2009","unstructured":"Wenzel, R. R. et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J. Am. Soc. Nephrol. 20, 655\u2013664 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"908_CR65","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","volume":"21","author":"JFE Mann","year":"2010","unstructured":"Mann, J. F. E. et al. Avosentan for overt diabetic nephropathy. J. Am. Soc. Nephrol. 21, 527 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"908_CR66","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/clpt.2009.15","volume":"85","author":"J Smolander","year":"2009","unstructured":"Smolander, J. et al. Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects. Clin. Pharmacol. Ther. 85, 628\u2013634 (2009).","journal-title":"Clin. Pharmacol. Ther."},{"key":"908_CR67","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S2213-8587(23)00168-7","volume":"11","author":"HJ Heerspink","year":"2023","unstructured":"Heerspink, H. J. et al. People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action. Lancet Diabetes Endocrinol. 11, 536\u2013540 (2023).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"908_CR68","unstructured":"A study of the effect and safety of sparsentan in the treatment of patients with IgA nephropathy (PROTECT). US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03762850 (2024)."},{"key":"908_CR69","unstructured":"Atrasentan in patients with IgA nephropathy (ALIGN). US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04573478 (2024)."},{"key":"908_CR70","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000538","author":"HJL Heerspink","year":"2024","unstructured":"Heerspink, H. J. L. et al. The selective endothelin receptor antagonist SC0062 in IgA nephropathy: a randomized double-blind placebo-controlled clinical trial. J. Clin. Soc. Nephrol. https:\/\/doi.org\/10.1681\/ASN.0000000538 (2024).","journal-title":"J. Clin. Soc. Nephrol."},{"key":"908_CR71","unstructured":"Randomized, double-blind, safety and efficacy study of RE-021 (sparsentan) in focal segmental glomerulosclerosis (DUET). US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01613118 (2024)."},{"key":"908_CR72","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa2308550","volume":"389","author":"MN Rheault","year":"2023","unstructured":"Rheault, M. N. et al. Sparsentan versus Irbesartan in focal segmental glomerulosclerosis. N. Engl. J. Med. 389, 2436\u20132445 (2023).","journal-title":"N. Engl. J. Med."},{"key":"908_CR73","unstructured":"Atrasentan in patients with proteinuric glomerular diseases (AFFINITY). US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04573920 (2024)."},{"key":"908_CR74","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436\u20131446 (2020).","journal-title":"N. Engl. J. Med."},{"key":"908_CR75","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","volume":"9","author":"DC Wheeler","year":"2021","unstructured":"Wheeler, D. C. et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 9, 22\u201331 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"908_CR76","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.kint.2020.09.026","volume":"99","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L., Kohan, D. E. & de Zeeuw, D. New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction. Kidney Int. 99, 346\u2013349 (2020).","journal-title":"Kidney Int."},{"key":"908_CR77","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","volume":"402","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink, H. J. L. et al. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial. Lancet 402, 2004\u20132017 (2023).","journal-title":"Lancet"},{"key":"908_CR78","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ndt\/gfad183","volume":"39","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink, H. J. L. et al. Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial. Nephrol. Dial. Transplant. 39, 414\u2013425 (2023).","journal-title":"Nephrol. Dial. Transplant."},{"key":"908_CR79","unstructured":"Study to investigate efficacy, safety, and tolerability of zibotentan\/dapagliflozin compared to dapagliflozin in participants with chronic kidney disease and high proteinuria (ZENITH high proteinuria). US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06087835 (2024)."},{"key":"908_CR80","unstructured":"Randomized, double-blind, placebo-controlled, crossover study of atrasentan in subjects with IgA nephropathy (ASSIST). US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05834738 (2024)."},{"key":"908_CR81","unstructured":"Ambrisentan sotagliflozin and prevention of renal injury; a randomized evaluation (ASPIRE). US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06072326 (2023)."},{"key":"908_CR82","unstructured":"A study to investigate safety and effect of sparsentan in combination with SGLT2 inhibition in participants with IgAN. US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05856760 (2024)."},{"key":"908_CR83","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1152\/ajpcell.00301.2011","volume":"302","author":"V Bugaj","year":"2012","unstructured":"Bugaj, V., Mironova, E., Kohan, D. E. & Stockand, J. D. Collecting duct-specific endothelin b receptor knockout increases ENaC activity. Am. J. Physiol. Cell Physiol. 302, 188\u2013194 (2012).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"908_CR84","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1152\/ajprenal.90321.2008","volume":"295","author":"V Bugaj","year":"2008","unstructured":"Bugaj, V. et al. Regulation of the epithelial Na+ channel by endothelin-1 in rat collecting duct. Am. J. Physiol. Renal Physiol. 295, 1063\u20131070 (2008).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"908_CR85","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1471-2369-13-166","volume":"13","author":"D Stuart","year":"2012","unstructured":"Stuart, D. et al. Disruption of the endothelin A receptor in the nephron causes mild fluid volume expansion. BMC Nephrol. 13, 166 (2012).","journal-title":"BMC Nephrol."},{"key":"908_CR86","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/jpet.113.205286","volume":"346","author":"D Stuart","year":"2013","unstructured":"Stuart, D., Chapman, M., Rees, S., Woodward, S. & Kohan, D. E. Myocardial, smooth muscle, nephron, and collecting duct gene targeting reveals the organ sites of endothelin A receptor antagonist fluid retention. J. Pharmacol. Exp. Ther. 346, 182\u2013189 (2013).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"908_CR87","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1111\/bph.16504","volume":"181","author":"H Yu","year":"2024","unstructured":"Yu, H. et al. The role of venous capacity in fluid retention with endothelin A antagonism: mathematical modelling of the RADAR trial. Br. J. Pharmacol. 181, 4693\u20134707 (2024).","journal-title":"Br. J. Pharmacol."},{"key":"908_CR88","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1183\/09031936.00194810","volume":"37","author":"N Gali\u00e8","year":"2011","unstructured":"Gali\u00e8, N., Hoeper, M. M., Gibbs, J. S. R. & Simonneau, G. Liver toxicity of sitaxentan in pulmonary arterial hypertension. Eur. Respir. J. 37, 475\u2013476 (2011).","journal-title":"Eur. Respir. J."},{"key":"908_CR89","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.yrtph.2012.05.017","volume":"64","author":"K Owen","year":"2012","unstructured":"Owen, K., Cross, D. M., Derzi, M., Horsley, E. & Stavros, F. L. An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin\u00ae), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension. Regul. Toxicol. Pharmacol. 64, 95\u2013103 (2012).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"908_CR90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087548","volume":"9","author":"EI Lepist","year":"2014","unstructured":"Lepist, E. I. et al. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes. PLoS ONE 9, e87548 (2014).","journal-title":"PLoS ONE"},{"key":"908_CR91","volume":"5","author":"A Wei","year":"2016","unstructured":"Wei, A. et al. Clinical adverse effects of endothelin receptor antagonists: insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials. J. Am. Heart Assoc. 5, e003896 (2016).","journal-title":"J. Am. Heart Assoc."},{"key":"908_CR92","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1111\/dom.15103","volume":"25","author":"DE Kohan","year":"2023","unstructured":"Kohan, D. E., Liew, A., Tang, S. C. W., Barratt, J. & Heerspink, H. J. L. Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes. Metab. 25, 2410\u20132412 (2023).","journal-title":"Diabetes Obes. Metab."},{"key":"908_CR93","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/dom.12864","volume":"19","author":"MJ Pena","year":"2017","unstructured":"Pena, M. J. et al. The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. Diabetes Obes. Metab. 19, 749\u2013753 (2017).","journal-title":"Diabetes Obes. Metab."},{"key":"908_CR94","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.lfs.2012.01.011","volume":"91","author":"DL Andress","year":"2012","unstructured":"Andress, D. L. et al. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD). Life Sci. 91, 739\u2013742 (2012).","journal-title":"Life Sci."},{"key":"908_CR95","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1681\/ASN.2012040355","volume":"24","author":"N Dhaun","year":"2013","unstructured":"Dhaun, N. et al. Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD. J. Am. Soc. Nephrol. 24, 31\u201336 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"908_CR96","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1046\/j.1523-1755.1998.06722.x","volume":"54","author":"SJ Pinto-Sietsma","year":"1998","unstructured":"Pinto-Sietsma, S. J. & Paul, M. A role for endothelin in the pathogenesis of hypertension: fact or fiction? Kidney Int. 54, S115\u2013S121 (1998).","journal-title":"Kidney Int."},{"key":"908_CR97","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s11906-003-0071-4","volume":"5","author":"M Iglarz","year":"2003","unstructured":"Iglarz, M. & Schiffrin, E. L. Role of endothelin-1 in hypertension. Curr. Hypertens. Rep. 5, 144\u2013148 (2003).","journal-title":"Curr. Hypertens. Rep."},{"key":"908_CR98","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/hr.2014.160","volume":"38","author":"S Akter","year":"2014","unstructured":"Akter, S. et al. Higher circulatory level of endothelin-1 in hypertensive subjects screened through a cross-sectional study of rural Bangladeshi women. Hypertens. Res. 38, 208\u2013212 (2014).","journal-title":"Hypertens. Res."},{"key":"908_CR99","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3390\/ijms17081182","volume":"17","author":"K Kostov","year":"2016","unstructured":"Kostov, K., Blazhev, A., Atanasova, M. & Dimitrova, A. Serum concentrations of endothelin-1 and matrix metalloproteinases-2, -9 in pre-hypertensive and hypertensive patients with type 2 diabetes. Int. J. Mol. Sci. 17, 1182 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"908_CR100","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3390\/pathophysiology28040031","volume":"28","author":"K Kostov","year":"2021","unstructured":"Kostov, K. & Blazhev, A. Circulating levels of endothelin-1 and big endothelin-1 in patients with essential hypertension. Pathophysiology 28, 489\u2013495 (2021).","journal-title":"Pathophysiology"},{"key":"908_CR101","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3390\/life11090986","volume":"11","author":"K Kostov","year":"2021","unstructured":"Kostov, K. & Kim, J. The causal relationship between endothelin-1 and hypertension: focusing on endothelial dysfunction, arterial stiffness, vascular remodeling, and blood pressure regulation. Life 11, 986 (2021).","journal-title":"Life"},{"key":"908_CR102","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJM199803193381202","volume":"338","author":"H Krum","year":"1998","unstructured":"Krum, H., Viskoper, R., Lacourciere, Y., Budde, M. & Charlon, V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N. Engl. J. Med. 338, 784\u2013791 (1998).","journal-title":"N. Engl. J. Med."},{"key":"908_CR103","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(09)61500-2","volume":"374","author":"MA Weber","year":"2009","unstructured":"Weber, M. A. et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 374, 1423\u20131431 (2009).","journal-title":"Lancet"},{"key":"908_CR104","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/HYPERTENSIONAHA.110.156976","volume":"56","author":"GL Bakris","year":"2010","unstructured":"Bakris, G. L. et al. Divergent results using clinic and ambulatory blood pressures. Hypertension 56, 824\u2013830 (2010).","journal-title":"Hypertension"},{"key":"908_CR105","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","volume":"400","author":"MP Schlaich","year":"2022","unstructured":"Schlaich, M. P. et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet 400, 1927\u20131937 (2022).","journal-title":"Lancet"},{"key":"908_CR106","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/sdi.12196","volume":"27","author":"SN Davison","year":"2014","unstructured":"Davison, S. N., Koncicki, H. & Brennan, F. Pain in chronic kidney disease: a scoping review. Semin. Dial. 27, 188\u2013204 (2014).","journal-title":"Semin. Dial."},{"key":"908_CR107","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jchemneu.2003.12.002","volume":"27","author":"V Naidoo","year":"2004","unstructured":"Naidoo, V., Naidoo, S., Mahabeer, R. & Raidoo, D. M. Cellular distribution of the endothelin system in the human brain. J. Chem. Neuroanat. 27, 87\u201398 (2004).","journal-title":"J. Chem. Neuroanat."},{"key":"908_CR108","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2147\/JPR.S65923","volume":"7","author":"TP Smith","year":"2014","unstructured":"Smith, T. P., Haymond, T., Smith, S. N. & Sweitzer, S. M. Evidence for the endothelin system as an emerging therapeutic target for the treatment of chronic pain. J. Pain. Res. 7, 531\u2013545 (2014).","journal-title":"J. Pain. Res."},{"key":"908_CR109","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.npep.2007.12.001","volume":"42","author":"G Hans","year":"2008","unstructured":"Hans, G., Deseure, K. & Adriaensen, H. Endothelin-1-induced pain and hyperalgesia: a review of pathophysiology, clinical manifestations and future therapeutic options. Neuropeptides 42, 119\u2013132 (2008).","journal-title":"Neuropeptides"},{"key":"908_CR110","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1523\/JNEUROSCI.21-03-00999.2001","volume":"21","author":"JD Pomonis","year":"2001","unstructured":"Pomonis, J. D., Rogers, S. D., Peters, C. M., Ghilardi, J. R. & Mantyh, P. W. Expression and localization of endothelin receptors: implications for the involvement of peripheral glia in nociception. J. Neurosci. 21, 999\u20131006 (2001).","journal-title":"J. Neurosci."},{"key":"908_CR111","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jpain.2008.09.009","volume":"10","author":"A Khodorova","year":"2009","unstructured":"Khodorova, A., Montmayeur, J. P. & Strichartz, G. Endothelin receptors and pain. J. Pain. 10, 4\u201328 (2009).","journal-title":"J. Pain."},{"key":"908_CR112","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.neulet.2009.03.055","volume":"457","author":"EM Motta","year":"2009","unstructured":"Motta, E. M., Chichorro, J. G. & Rae, G. A. Role of ETA and ETB endothelin receptors on endothelin-1-induced potentiation of nociceptive and thermal hyperalgesic responses evoked by capsaicin in rats. Neurosci. Lett. 457, 146\u2013150 (2009).","journal-title":"Neurosci. Lett."},{"key":"908_CR113","first-page":"PL397","volume":"61","author":"M D\u2019Amico","year":"1997","unstructured":"D\u2019Amico, M., Di Filippo, C. & Rossi, F. Selective and non-selective et antagonists reveal an ETA\/ETB receptor mediated ET-1-induced antinociceptive effect in PAG area of mice. Life Sci. 61, PL397\u2013PL401 (1997).","journal-title":"Life Sci."},{"key":"908_CR114","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.neulet.2007.03.008","volume":"418","author":"G Hans","year":"2007","unstructured":"Hans, G., Deseure, K., Robert, D. & De Hert, S. Neurosensory changes in a human model of endothelin-1 induced pain: a behavioral study. Neurosci. Lett. 418, 117\u2013121 (2007).","journal-title":"Neurosci. Lett."},{"key":"908_CR115","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.kint.2023.08.014","volume":"104","author":"KW Chan","year":"2023","unstructured":"Chan, K. W. et al. Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease. Kidney Int. 104, 1219\u20131226 (2023).","journal-title":"Kidney Int."},{"key":"908_CR116","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"P Rossing","year":"2022","unstructured":"Rossing, P. et al. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 102, S1\u2013S127 (2022).","journal-title":"Kidney Int."},{"key":"908_CR117","doi-asserted-by":"crossref","first-page":"F1173","DOI":"10.1152\/ajprenal.00040.2019","volume":"316","author":"J Dolinina","year":"2019","unstructured":"Dolinina, J., Rippe, A. & \u00d6berg, C. M. Sustained, delayed, and small increments in glomerular permeability to macromolecules during systemic ET-1 infusion mediated via the ETA receptor. Am. J. Physiol. Renal Physiol. 316, F1173\u2013F1179 (2019).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"908_CR118","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1254\/jjp.82.307","volume":"82","author":"T Kuro","year":"2000","unstructured":"Kuro, T. et al. Selective antagonism of the ETA receptor, but not the ETB receptor, is protective against ischemic acute renal failure in rats. Jpn. J. Pharmacol. 82, 307\u2013316 (2000).","journal-title":"Jpn. J. Pharmacol."},{"key":"908_CR119","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1046\/j.1523-1755.2001.0590041333.x","volume":"59","author":"JM Forbes","year":"2001","unstructured":"Forbes, J. M., Hewitson, T. D., Becker, G. J. & Jones, C. L. Simultaneous blockade of endothelin A and B receptors in ischemic acute renal failure is detrimental to long-term kidney function. Kidney Int. 59, 1333\u20131341 (2001).","journal-title":"Kidney Int."},{"key":"908_CR120","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1258\/rsmacta.44.1.111","volume":"44","author":"P Liss","year":"2003","unstructured":"Liss, P., Carlsson, P. O., Nygren, A., Palm, F. & Hansell, P. Et-A receptor antagonist BQ123 prevents radiocontrast media-induced renal medullary hypoxia. Acta Radiol. 44, 111\u2013117 (2003).","journal-title":"Acta Radiol."},{"key":"908_CR121","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.lfs.2012.02.002","volume":"91","author":"N Abu-Saleh","year":"2012","unstructured":"Abu-Saleh, N. et al. Involvement of the endothelin and nitric oxide systems in the pathogenesis of renal ischemic damage in an experimental diabetic model. Life Sci. 91, 669\u2013675 (2012).","journal-title":"Life Sci."},{"key":"908_CR122","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejphar.2014.03.002","volume":"730","author":"MM Helmy","year":"2014","unstructured":"Helmy, M. M., Helmy, M. W., Abd Allah, D. M., Abo Zaid, A. M. & Mohy El-Din, M. M. Selective ETA receptor blockade protects against cisplatin-induced acute renal failure in male rats. Eur. J. Pharmacol. 730, 133\u2013139 (2014).","journal-title":"Eur. J. Pharmacol."},{"key":"908_CR123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep43152","volume":"7","author":"C De Miguel","year":"2017","unstructured":"De Miguel, C. et al. Endothelin receptor-specific control of endoplasmic reticulum stress and apoptosis in the kidney. Sci. Rep. 7, 1\u201313 (2017).","journal-title":"Sci. Rep."},{"key":"908_CR124","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1093\/cvr\/cvz260","volume":"116","author":"KMM Colafella","year":"2020","unstructured":"Colafella, K. M. M. et al. Selective ETA vs. dual ETA\/B receptor blockade for the prevention of sunitinib-induced hypertension and albuminuria in WKY rats. Cardiovasc. Res. 116, 1779\u20131790 (2020).","journal-title":"Cardiovasc. Res."},{"key":"908_CR125","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000444719","volume":"43","author":"TW Harvey","year":"2016","unstructured":"Harvey, T. W., Engel, J. E. & Chade, A. R. Vascular endothelial growth factor and podocyte protection in chronic hypoxia: effects of endothelin-A receptor antagonism. Am. J. Nephrol. 43, 74\u201384 (2016).","journal-title":"Am. J. Nephrol."},{"key":"908_CR126","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0014-2999(99)00535-X","volume":"381","author":"T Shimizu","year":"1999","unstructured":"Shimizu, T., Hata, S., Kuroda, T., Mihara, S. I. & Fujimoto, M. Different roles of two types of endothelin receptors in partial ablation-induced chronic renal failure in rats. Eur. J. Pharmacol. 381, 39\u201349 (1999).","journal-title":"Eur. J. Pharmacol."},{"key":"908_CR127","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/ki.2013.477","volume":"85","author":"AR Chade","year":"2014","unstructured":"Chade, A. R., Stewart, N. J. & Peavy, P. R. Disparate effects of single endothelin-A and -B receptor blocker therapy on the progression of renal injury in advanced renovascular disease. Kidney Int. 85, 833\u2013844 (2014).","journal-title":"Kidney Int."},{"key":"908_CR128","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1681\/ASN.2014040323","volume":"26","author":"AR Chade","year":"2015","unstructured":"Chade, A. R., Tullos, N., Stewart, N. J. & Surles, B. Endothelin-A receptor antagonism after renal angioplasty enhances renal recovery in renovascular disease. J. Am. Soc. Nephrol. 26, 1071\u20131080 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"908_CR129","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1124\/jpet.111.178988","volume":"338","author":"MA Saleh","year":"2011","unstructured":"Saleh, M. A., Pollock, J. S. & Pollock, D. M. Distinct actions of endothelin A-selective versus combined endothelin A\/B receptor antagonists in early diabetic kidney disease. J. Pharmacol. Exp. Ther. 338, 263\u2013270 (2011).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"908_CR130","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/00007890-199909270-00005","volume":"68","author":"C Braun","year":"1999","unstructured":"Braun, C. et al. Prevention of chronic renal allograft rejection in rats with an oral endothelin A receptor antagonist. Transplantation 68, 739\u2013746 (1999).","journal-title":"Transplantation"},{"key":"908_CR131","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/00005344-200010000-00003","volume":"36","author":"C Braun","year":"2000","unstructured":"Braun, C. et al. Treatment with a combined endothelin A\/B-receptor antagonist does not prevent chronic renal allograft rejection in rats. J. Cardiovasc. Pharmacol. 36, 428\u2013437 (2000).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"908_CR132","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1681\/ASN.2016070711","volume":"28","author":"M Kasztan","year":"2017","unstructured":"Kasztan, M. et al. Long-term endothelin-A receptor antagonism provides robust renal protection in humanized sickle cell disease mice. J. Am. Soc. Nephrol. 28, 2443\u20132458 (2017).","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-024-00908-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-024-00908-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-024-00908-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T08:04:31Z","timestamp":1740038671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-024-00908-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":132,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["908"],"URL":"https:\/\/doi.org\/10.1038\/s41581-024-00908-z","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]},"assertion":[{"value":"30 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.E.K. has consulted for AstraZeneca, Chinook Therapeutics and Travere Therapeutics. N.D. has consulted for Travere Therapeutics. I.L.N. has received honoraria for scientific presentations from AstraZeneca, Bayer, Roche and Novartis. A.L. has consulted for DaVita Inc, Alnylam Pharmaceuticals, Baxter Healthcare, Bayer, Boehringer-Ingelheim, Chinook Therapeutics, Eledon Pharmaceuticals, George Clinical, Kira Pharmaceuticals, Otsuka Pharmaceuticals and ProKidney, and received honoraria from Alnylam Pharmaceuticals, AstraZeneca, Baxter Healthcare, Bayer, Boehringer-Ingelheim, Chinook Therapeutics and Otsuka Pharmaceuticals. H.J.L.H. has consulted for AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Behring, Dimerix, Eli-Lilly, Gilead, Janssen, Merck, Novo Nordisk, ProKidney, Travere Therapeutics and Vifor Fresenius, and received research support from AstraZeneca, Boehringer Ingelheim, Janssen and Novo Nordisk. J.D.S. has no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}